Literature DB >> 31757379

Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.

Wenfeng Fang1, Jiadi Gan1, Yihua Huang1, Huaqiang Zhou1, Li Zhang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31757379     DOI： 10.1016/j.jtho.2019.07.018

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

1.  Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment.

Authors:  Hong-Shuai Li; Guang-Jian Yang; Yan Wang
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

Review 2.  Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.

Authors:  Takamasa Koga; Kenichi Suda; Tetsuya Mitsudomi
Journal:  Cancer Sci       Date:  2022-01-23       Impact factor: 6.716

3.  Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation Receiving Third-Generation EGFR-TKI Osimertinib Treatment.

Authors:  Xin Tang; Yuan Li; Wei-Feng Yan; Wen-Lei Qian; Tong Pang; You-Ling Gong; Zhi-Gang Yang
Journal:  Front Oncol       Date:  2021-09-29       Impact factor: 6.244

4.  Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report.

Authors:  Koichiro Nozaki; Satoshi Watanabe; Kazuto Nishio; Kazuko Sakai; Toshiaki Kikuchi
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

Review 5.  The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy.

Authors:  Matteo Canale; Kalliopi Andrikou; Ilaria Priano; Paola Cravero; Luigi Pasini; Milena Urbini; Angelo Delmonte; Lucio Crinò; Giuseppe Bronte; Paola Ulivi
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

6.  L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment.

Authors:  Meihui Li; Jing Qin; Fajun Xie; Lei Gong; Na Han; Hongyang Lu
Journal:  Discov Oncol       Date:  2022-08-09

7.  Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.

Authors:  Jacqueline H Starrett; Alexis A Guernet; Maria Emanuela Cuomo; Kamrine E Poels; Iris K van Alderwerelt van Rosenburgh; Amy Nagelberg; Dylan Farnsworth; Kristin S Price; Hina Khan; Kumar Dilip Ashtekar; Mmaserame Gaefele; Deborah Ayeni; Tyler F Stewart; Alexandra Kuhlmann; Susan M Kaech; Arun M Unni; Robert Homer; William W Lockwood; Franziska Michor; Sarah B Goldberg; Mark A Lemmon; Paul D Smith; Darren A E Cross; Katerina Politi
Journal:  Cancer Res       Date:  2020-03-19       Impact factor: 12.701
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.